RTW Biotech Opportunities Ltd (LSE: RTWG), a closed-ended investment fund focused on the biopharmaceutical and medical technology sectors, announced on 13 November 2026 that it repurchased 340,794 ordinary shares on 12 November 2026 at a price of $2.48 per share. The bought-back shares will be held in treasury and will carry no voting rights, reducing the total voting rights in the company to 318,123,228. The buyback was conducted under authority granted by shareholders at the company's Annual General Meeting in June 2026, with Jefferies International Limited acting as broker for the transaction.

Key Points

  • RTW Biotech Opportunities Ltd (LSE: RTWG) — closed-ended investment fund managed by RTW Investments, LP
  • 340,794 ordinary shares repurchased on 12 November 2026 at $2.48 per share and transferred to treasury
  • Total voting rights now stand at 318,123,228 following settlement; 27,844,212 shares held in treasury attract no voting rights
  • Investors should monitor further buyback activity ahead of the next AGM shareholder authority expected in 2027

RTW Biotech Opportunities Repurchases Shares at $2.48 and Transfers Them to Treasury

The company's announcement confirms that 340,794 ordinary shares were acquired on 12 November 2026 at a price of $2.48 per share and will be held in treasury rather than cancelled. Following settlement, the total issued ordinary share capital stands at 345,967,440 shares, of which 27,844,212 are now held in treasury and carry no voting rights. The resulting total voting rights figure of 318,123,228 is published to allow shareholders to assess whether they are required to make notifications under the FCA's Disclosure and Transparency Rules regarding changes to their interests in the company.

AGM Authority Granted in June 2026 Permits Repurchase of Up to 14.99% of Ordinary Shares

The share repurchase was conducted under a shareholder mandate approved at the company's Annual General Meeting in June 2026, which permits RTW Biotech Opportunities Ltd to buy back a maximum of 14.99% of its ordinary shares. The announcement states that the authority remains in force until the next shareholder authority is granted — expected at the AGM in 2027 — or until it is expressly revoked by shareholders. The actual volume of shares repurchased will depend on prevailing market conditions, and the company is prohibited from paying a price that would represent a premium to net asset value.

Jefferies International Acts as Broker as RTW Investments Manages the Buyback Programme

RTW Biotech Opportunities Ltd has instructed Jefferies International Limited as its broker for the buyback programme, in accordance with FCA Listing Rules and the company's general repurchase authority. The fund is managed by RTW Investments, LP, a healthcare-focused investment firm with scientific expertise across biopharmaceutical and medical technology sectors. The company invests in businesses developing next-generation therapies and technologies, targeting transformative assets with high growth potential. The company's current stated intention is to retain all repurchased shares in treasury rather than to cancel them.